You are here

Targeting STT3A and STT3B to Block Flavivirus Replication

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AI134531-01
Agency Tracking Number: R41AI134531
Amount: $593,950.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA16-303
Timeline
Solicitation Year: 2016
Award Year: 2017
Award Start Date (Proposal Award Date): 2017-08-16
Award End Date (Contract End Date): 2019-07-31
Small Business Information
23 BUSINESS PARK DRIVE
Branford, CT 06405-2904
United States
DUNS: 078625067
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 MICHAEL VANZANDT
 (203) 208-2523
 mvanzandt@nedp.com
Business Contact
 MICHAEL VANZANDT
Phone: (203) 208-2523
Email: mvanzandt@nedp.com
Research Institution
 YALE UNIVERSITY
 
P.O. Box 208327
NEW HAVEN, CT 06520-8327
United States

 Nonprofit college or university
Abstract

AbstractMosquito borne flaviviruses cause disease worldwidewith members such as dengue virusDENVZika
virusZIKVand west nile virusWNVinfecting more thanmillion individuals annuallyThe availability of
small molecule antivirals that reduce flavivirus infection therefore could have an immediate and substantial
impact on public health programs that seek to improve outcomes for populations infected with WNVDENVand ZIKVRecentlygenome wide screening using either insertional mutagenesis or CRISPR Casknockout approaches have identified subunits of the oligosaccharyltransferaseOSTspecifically STT A and
STT Bas essential for the flavivirus life cycleDrug discovery efforts using a novel bioluminescent reporter
that detects inhibition of OST function have also had recent success with the identification of novel small
molecules that target the OSTThis class of inhibitors directly engage with the STT A and STT B
subunits and therefore have the potential to be antiviral agents for the treatment of flavivirus infectionThe
proposed research seeks to structurally optimize the potency and solubility of this drug like small molecule
series in order to advance this therapeutic strategy for preclinical testing

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government